Latest News and Press Releases

Tekjur á fyrsta fjórðungi ársins jukust samanborið við sama tímabil í fyrra, úr 0,8 milljónum dollara í 15,9 milljónir dollaraFimmta lyf Alvotech hefur verið tekið til klínískra rannsókna á...

Revenue for the first three months of 2023 increased to $15.9 million, compared to $0.8 million for the same period in 2022Confirmatory patient study for AVT05, a proposed biosimilar for Simponi® and...

REYKJAVIK, Iceland, May 17, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan...

Alvotech (NASDAQ First North: ALVO) tilkynnti í dag um þátttöku í fyrstu árlegu ráðstefnu fjárfestingabankans Morgan Stanley um sjálfbærar fjárfestingar, þann 22. maí nk. Fulltrúar Alvotech sitja...

Hlutfall karla og kvenna í starfsliði Alvotech er nú jafnt og óútskýrður kynbundinn launamunur dróst saman úr 5,2% í desember 2020 í 1,6% í desember 2022Jafnréttisstefna Alvotech fylgir íslenskri...

Alvotech’s global workforce is now evenly split between females and males, and the unexplained gender pay gap has been reduced to 1.6% from 5.2% in December 2020Alvotech’s Equality Policy, which is...

Alvotech’s global workforce is now evenly split between females and males, and the unexplained gender pay gap has been reduced to 1.6% from 5.2% in December 2020Alvotech’s Equality Policy, which is...

Polifarma öðlast rétt til að markaðssetja AVT06, fyrirhugaða líftæknilyfjahliðstæðu við Eylea® (aflibercept) í Tyrklandi Alvotech (NASDAQ: ALVO) tilkynnti í dag um undirritun samnings við Polifarma...

Polifarma will commercialize AVT06, a proposed biosimilar to Eylea® (aflibercept), in Turkey  Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of...